Clinical Treatment Score post-5 years as a predictor of late distant recurrence in hormone receptor-positive breast cancer: systematic review and meta-analysis.
Amber ShresthaCarolyn M CullinaneDenis EvoyJames GeraghtyJane RothwellJanice WalsheDamien McCartanEnda McDermottRuth PrichardPublished in: The British journal of surgery (2022)
The CTS5 can predict late distant recurrence risk in pre- and postmenopausal hormone receptor-positive breast cancer patients. CTS5 overestimates the risk for high-risk patients and thus, its use in these patients warrants caution.